Coldrif deaths
Plea in SC seeks probe into deaths in states due to cough syrup consumption
This story was originally published at 12:51 IST on 7 October 2025
Register to read our real-time news.Informist, Tuesday, Oct. 7, 2025
--Plea in SC seeks probe into deaths in states due to cough syrup consumption
NEW DELHI – A public interest litigation was filed in the Supreme Court Tuesday seeking a Central Bureau of Investigation probe into the deaths of children in Madhya Pradesh and other states allegedly due to consumption of a cough syrup. The petitioner, Vishal Tiwari, an advocate, has sought the transfer of all pending first information reports relating to the deaths from all states to the Central Bureau of Investigation.
Tiwari has sought the apex court's directions to the government for constituting a National Judicial Commission or an expert committee, headed by a retired judge of the Supreme Court, to conduct a comprehensive enquiry into the manufacture, regulation, testing and distribution of contaminated cough syrups containing diethylene glycol and ethylene glycol. The petitioner sought measures from the committee for the safety and standard of medicines.
The petitioner seeks the top court to order the government to immediately recall, seize and prohibit the sale and distribution of all batches of Coldrif cough syrup, manufactured by Sresan Pharma Pvt. Ltd., Kancheepuram in Tamil Nadu, or any related companies pending toxicology clearance and verification of safety standards by independent laboratories.
The case has its genesis from at least 14 children dying of kidney failure after consuming cough medicine branded Coldrif syrup. The syrup contained the toxin diethylene glycol in quantities nearly 500 times the permissible limit. Diethylene glycol or ethylene glycol was also found in Indian-made cough syrups that had killed at least 141 children in Gambia, Uzbekistan and Cameroon since 2022, and another 12 children in India in 2019. End
Reported by Surya Tripathi
Edited by Deepshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
